Indicaciones de derivación del paciente con movimientos anormales de medicina primaria a especializada. Aspectos de la valoración laboral del paciente con movimientos anormales

  1. Hernández, J.A. Burguera
  2. Piudo, M.R. Luquin
  3. Alonso-Navarro, H.
  4. Jiménez-Jiménez, F.J.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2015

Series: 11

Issue: 74

Pages: 4479-4482

Type: Article

DOI: 10.1016/J.MED.2015.02.015 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Movement disorders are divided into rigid-akinetic syndromes (Parkinson's disease and parkinsonism) and dyskinetic (tremor, chorea, tribalism, athetosis, dystonia, myoclonus, tics, tardive dyskinesias and motor stereotypies). In this diagnostic-therapeutic protocol indications referring patients to specific queries movement disorders, with special emphasis on diagnostic and therapeutic stages of Parkinson's disease and aspects of job evaluation latter are summarized.

Bibliographic References

  • Alonso-Navarro H, Jiménez-Jiménez FJ, García-Martín E, Agúndez JAG. Ge-nomic and pharmacogenomic biomarkers of Parkinson’s disease. Curr Drug Metab. 2014;15:129-81.
  • Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Survival of Parkinson ́s disease patients in a large prospective cohort of male health professionals. Mov Disord. 2006;21:1002-7.
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mor-tality. Neurology. 1967;17:427-42.
  • Hoehn MM. Parkinson ́s disease: progression and mortality. Adv Neurol. 1986;45:457-61.
  • Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG. Ce-rebrospinal fluid biochemical studies in patients with Parkinson’s disease: towards a potential search for biomarkers for this disease. Front Cell Neurosci. 2014;8:369.
  • Leibson CL, Maraganore DM, Bower JH, Ransom JE, O ́Brien PC, Rocca WA. Comorbid conditions associated with Parkinson ́s disease. A popula-tion-based study. Mov Disord. 2006;21:446-55.
  • Lindgren P, von Campenhausen S, Spottke E, Siebert U, Dosel R. Cost of Parkinson’s disease in Europe. Eur J Neurol. 2005;12Suppl1:68-73.
  • MacMahon DG, Thomas S. Practical approach to quality of life in Parkinson ́s disease. J Neurol. 1998;245Suppl1:S19-S22.
  • Martí Doménech MJ. Indicaciones de derivación del paciente con movimientos anormales desde la medicina primaria a la especializa-da. Medicine. 2003:55-57.
  • McGhee DJM, Royle PL, Thompson PA, Wright DE, Zaicek JP, Counsell CE. A systematic review of biomarkers for disease progression in Parkinson ́s disease. BMC Neurology. 2013;13:35-48.
  • Ramos Arroyo M, Trujillo Tiebas, Mila M. Recomendaciones de buena prác-tica para el diagnóstico genético de la enfermedad de Huntington. Med Clin (Barc). 2012;138:584-8.
  • Siderowf A, Lang AE. Premotor Parkinson ́s disease: concepts and definitions. Mov Disord. 2012;27:608-16.
Data source: Dialnet